Accuracy of endoscopic ultrasound-guided needle aspiration specimens for molecular diagnosis of non-small-cell lung carcinoma.
Accuracy of endoscopic ultrasound-guided needle aspiration specimens for molecular diagnosis of non-small-cell lung carcinoma.
复制标题
超声内镜引导下针吸标本对非小细胞肺癌分子诊断的准确性
DOI：
10.12998/wjcc.v8.i21.5139
复制
发表时间：
2020-11-06
影响因子：
1.1
通讯作者：
Cao FL
中科院分区：
文献类型：
--
作者：
Su W;Tian XD;Liu P;Zhou DJ;Cao FL
Endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) are highly sensitive for diagnosing and staging lung cancer. In recent years, targeted therapy has shown great significance in the treatment of non-small cell lung carcinoma (NSCLC). Using these minimally invasive techniques to obtain specimens for molecular testing will provide patients with a more convenient diagnostic approach. To evaluate the feasibility and accuracy of tissue samples obtained using EUS-FNA and EBUS-TBNA for molecular diagnosis of NSCLC. A total of 83 patients with NSCLC underwent molecular testing using tissues obtained from EUS-FNA or EBUS-TBNA at the Tianjin Medical University Cancer Hospital from January 2017 to June 2019. All enrolled patients underwent chest computed tomography or positron emission tomography/computed tomography prior to puncture. We detected abnormal expression of EGFR, KRAS, MET, HER2, ROS1 and anaplastic lymphoma kinase protein. Two patients failed to complete molecular testing due to insufficient tumor tissue. The clinical features, puncture records, molecular testing results and targeted treatment in the remaining 81 patients were summarized. In a total of 99 tissue samples obtained from 83 patients, molecular testing was successfully completed in 93 samples with a sample adequacy ratio of 93.9% (93/99). Biopsy samples from two patients failed to provide test results due to insufficient tumor tissue. In the remaining 81 patients, 62 cases (76.5%) were found to have adenocarcinoma, 11 cases (13.6%) had squamous cell carcinoma, 3 cases (3.7%) had adenosquamous carcinoma and 5 cases (6.2%) had NSCLC-not otherwise specified. The results of molecular testing showed EGFR mutations in 21 cases (25.9%), KRAS mutations in 9 cases (11.1%), ROS-1 rearrangement in 1 case (1.2%) and anaplastic lymphoma kinase-positive in 5 cases (6.2%). Twenty-four patients with positive results received targeted therapy. The total effectiveness rate of targeted therapy was 66.7% (16/24), and the disease control rate was 83.3% (20/24). Tissue samples obtained by EUS-FNA or EBUS-TBNA are feasible for the molecular diagnosis of NSCLC and can provide reliable evidence for clinical diagnosis and treatment.
登录
查看更多内容
影响因子：
4.5
作者：
Dziedzic D;Peryt A;Szolkowska M;Langfort R;Orlowski T
通讯作者：
Orlowski T
支气管内超声引导下经支气管针吸标本用于肺癌分型和分子检测的确定因素
影响因子：
4.5
作者：
Zhang, Yujun;Xie, Fangfang;Sun, Jiayuan
通讯作者：
Sun, Jiayuan
影响因子：
20.4
作者：
Onozato, Ryoichi;Kosaka, Takayuki;Mitsudomi, Tetsuya
通讯作者：
Mitsudomi, Tetsuya
影响因子：
3.7
作者：
Kang HJ;Hwangbo B;Lee JS;Kim MS;Lee JM;Lee GK
通讯作者：
Lee GK
影响因子：
4.5
作者：
Colella S;Vilmann P;Konge L;Clementsen PF
通讯作者：
Clementsen PF